Jenburkt Pharmaceuticals Ltd
JENBURPHJenburkt Pharmaceuticals Ltd
JENBURPH


Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
12.06 | 2.41 | 2.15% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
44.48 | 5.11 | 0.70% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jenburkt Pharmaceuticals Limited is engaged in the manufacture of pharmaceutical formulations. The Company offers prescription and over-the-counter drugs.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 87.31 | 96.32 | 106.27 | 118.06 | 126.05 | 123.11 | 113.60 | 128.93 | 141.87 | 142.07 | ||||||||||
Raw Materials | 26.58 | 28.89 | 32.51 | 30.51 | 38.75 | 33.55 | 26.91 | 33.72 | 31.67 | 106.68 | ||||||||||
Power & Fuel Cost | 0.52 | 0.57 | 0.53 | 0.61 | 0.59 | 0.59 | 0.50 | 0.61 | 0.76 | |||||||||||
Employee Cost | 18.99 | 21.49 | 25.21 | 27.69 | 31.20 | 36.51 | 32.38 | 36.49 | 38.81 | |||||||||||
Selling & Administrative Expenses | 23.29 | 26.11 | 26.61 | 27.30 | 28.10 | 25.46 | 23.03 | 24.32 | 29.03 | |||||||||||
Operating & Other expenses | 0.58 | 0.07 | -1.27 | 4.78 | -0.95 | 3.03 | 6.62 | 1.59 | 6.12 | |||||||||||
EBITDA | 17.35 | 19.19 | 22.68 | 27.17 | 28.36 | 23.97 | 24.16 | 32.20 | 35.48 | 35.39 | ||||||||||
Depreciation/Amortization | 2.66 | 1.99 | 1.79 | 1.50 | 1.35 | 2.30 | 2.04 | 1.90 | 2.26 | 2.26 | ||||||||||
PBIT | 14.69 | 17.20 | 20.89 | 25.67 | 27.01 | 21.67 | 22.12 | 30.30 | 33.22 | 33.13 | ||||||||||
Interest & Other Items | 0.36 | 0.38 | 0.41 | 0.41 | 0.39 | 0.53 | 0.47 | 0.43 | 0.37 | 0.32 | ||||||||||
PBT | 14.33 | 16.82 | 20.48 | 25.26 | 26.62 | 21.14 | 21.65 | 29.87 | 32.85 | 32.81 | ||||||||||
Taxes & Other Items | 4.70 | 6.05 | 6.97 | 8.05 | 6.83 | 6.27 | 5.14 | 7.58 | 8.25 | 8.32 | ||||||||||
Net Income | 9.63 | 10.77 | 13.51 | 17.21 | 19.79 | 14.87 | 16.51 | 22.29 | 24.60 | 24.49 | ||||||||||
EPS | 20.71 | 23.16 | 29.06 | 37.26 | 43.12 | 32.40 | 35.97 | 48.57 | 54.65 | 55.49 | ||||||||||
DPS | 6.30 | 7.20 | 8.10 | 9.00 | 10.20 | 8.10 | 10.20 | 12.00 | 14.40 | 14.40 | ||||||||||
Payout ratio | 0.30 | 0.31 | 0.28 | 0.24 | 0.24 | 0.25 | 0.28 | 0.25 | 0.26 | 0.26 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Jenburkt Pharmaceuticals Ltd | 12.00 | 2.41 | 2.15% |
Sun Pharmaceutical Industries Ltd | 35.09 | 5.01 | 0.93% |
Cipla Ltd | 35.23 | 4.16 | 0.69% |
Dr Reddy's Laboratories Ltd | 21.37 | 4.14 | 0.69% |
Price Comparison
Compare JENBURPH with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Dividend Yield
Current dividend yield is 2.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹21.33 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 19, 2023
Dividend/Share
₹14.40
Ex DateEx Date
Jul 19, 2023
Cash Dividend
Ex DateEx DateJul 21, 2022
Dividend/Share
₹12.00
Ex DateEx Date
Jul 21, 2022
Cash Dividend
Ex DateEx DateAug 30, 2021
Dividend/Share
₹10.20
Ex DateEx Date
Aug 30, 2021
Cash Dividend
Ex DateEx DateMar 18, 2020
Dividend/Share
₹8.10
Ex DateEx Date
Mar 18, 2020
Cash Dividend
Ex DateEx DateJul 22, 2019
Dividend/Share
₹10.20
Ex DateEx Date
Jul 22, 2019
News & Opinions
Pharma stock declares ₹702 share buyback at a premium of 13%
1 year ago•Livemint
Dividend paying pharma stock to consider share buyback
1 year ago•Livemint
Jenburkt Pharmaceuticals standalone net profit rises 40.56% in the September 2021 quarter
2 years ago•Business Standard
Jenburkt Pharmaceuticals standalone net profit declines 16.02% in the March 2021 quarter
2 years ago•Business Standard
Stocks in news: ITC, Infosys, PVR, MTAR Tech, SBI, Panacea Biotec and Radico Khaitan
2 years ago•Economic Times
Jenburkt Pharmaceuticals standalone net profit rises 28.23% in the December 2020 quarter
2 years ago•Business Standard
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 3.74%, vs industry avg of 8.45%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.06% to 0.04%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 7.41%, vs industry avg of 9.82%